Long SPRB on Rare Disease Catalyst

3 days ago

"Why long SPRB? Well, this is my wheelhouse. Its a rare disease drug company and they have a rare disease from a drug from Biomearin. Biomearin was kind of like the rare disease kings and, um, yeah, basically, um, the drug works, um, really well and, um, itll get FDA approval and itll sell a lot and thats really it. Its worth like 5x what its trading at."

The speaker recommends a long position in SPRB, citing its rare disease focus and the potential for FDA approval as key catalysts. The claim is that the drug is undervalued, trading at approximately one-fifth of its potential value.

Related Stocks